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1. GENERAL INTRODUCTION 
1.1. History of Japanese encephalitis virus 
One report based on evolutional analysis suggests that Japanese encephalitis 
virus (JEV) was originated from its ancestral virus, evolved into the various genotypes 
(I-V) in the Indonesia-Malaysia region, and then spread across Asia (Mohammed et al., 
2011). Epidemics of encephalitis in humans and horses were first described in Japan in 
the 1870s, and one large endemic occurred in 1924. The pathogen was a filterable agent 
from human brain, but had not been identified or characterized (Miyake, 1964). The first 
JEV isolate, Nakayama strain, was isolated in 1935 from the brain of a fatal human case 
(Lewis et al., 1947), and the other JEV was also recovered from brain of a sick horse in 
1937 (Nakamura et al., 1967). Also, as mosquito transmission of JEV was suspected 
during the early 1930s, isolation of JEV from Culex (C.) tritaeniorhynchus in Okayama 
Prefecture, Japan, was reported in 1938 (Mitamura et al., 1938). Further studies identified 
that pigs and birds were the principle amplifiers and C. tritaeniorhynchus was responsible 
for transmission of JEV among these vertebrates and from amplifier to humans and horses 
(Buescher et al., 1959). Subsequently, JEV has been found throughout Southeast Asia and 
Western Pacific regions, and the virus was most recently isolated in Papua New Guinea 
and the Torres Straits of Australia (Hanna et al., 1996; Johansen et al., 2000; Mackenzie 
et al., 2001).  
1.2. Virus properties  
 JEV is a member of genus Flavivirus, family Flaviviridae, and closely related to 
West Nile virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, which all 
belong to Japanese encephalitis serocomplex (Mackenzie et al., 2002).  
 Flavivirus is a single stranded positive sense RNA virus wrapped in a 
nucleocapsid and surrounded by a lipid envelope. The length of RNA genome is 
approximately 11kb and encodes 3 structural proteins, capsid protein (C), precursor to the 
membrane protein (prM) and envelope protein (E), and 7 nonstructural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, NS5) (Castle et al., 1985, 1986; Rice et al., 1985; 
Wengler et al., 1985).  
 The prM protein is cleaved during maturation and only M protein is incorporated 
into the virion (Markoff, 1989). The pr protein is produced during maturation of virus 
particles within the secretory pathway, and is a small proteolytic fragment of the precursor 
prM protein (Stadler et al., 1997). The pr protein can protect immature virions against 
premature fusion with the host membrane (Zhang et al., 2003). Co-synthesis of the prM 
protein with the E protein is necessary for proper folding, membrane association, and 
assembly of the E protein (Konishi et al., 1993).  
 The E protein is the major antigenic determinant on virus particle, plays an 
important role in fusion during virus entry (Wengler et al., 1985), and associates with 
induction of protective neutralizing antibody response in hosts (Kimura-Kuroda et al., 
1988). The E protein is a head-to-tail homodimer with three structurally distinct domains, 
-barrel (domain I, amino acids 1-51, 134-195, 284-296), an elongated 
dimerization region (domain II, amino acids 52-133, 196-283), and a C-terminal 
immunoglobulin-like module (domain III, amino acids 297-395) (Luca et al., 2012; 
Nybakken et al., 2006; Rey et al., 1995). The domain I and domain III contain virus-
specific epitopes, while domain II contains flavivirus cross-reactive epitopes (Mandl et 
al., 1989). 
  Although the C protein is the lowest conserved region among flavivirus 
proteins, the structural properties, such as hydrophobicity profile, abundance of basic 
amino acid residues, and secondary and tertiary structures, are well conserved (Dokland 
et al., 2004; Jones et al., 2003; Ma et al., 2004). Since the C protein has RNA-binding 
ability by the basic amino acid clusters at its amino and carboxyl termini, it is believed 
that it binds to the genomic RNA to form a nucleocapsid (Khromykh et al., 1996). 
 The NS1 protein appears to be essential for virus viability, and contains two 
conserved N-glycosylation sites and 12 invariant cysteine residues (Lee et al., 1989; 
Mason, 1989). The NS1 protein exists briefly as a monomer and then undergoes 
dimerization within the host cells (Winkler et al., 1989). Also, the NS1 protein is released 
from infected cells as a hexamer, and it forms a lipoprotein particle with an open barrel 
protein shell and a prominent central channel rich in lipids (Flamand et al., 1999; Gutsche 
et al., 2011). Although it is suggested that the NS1 protein plays a role in viral RNA 
replication (Hall et al., 1999), a function of the NS1 protein have been still unclear.  
 The NS2A protein is a hydrophobic, multifunctional, and membrane-associated 
protein involved in RNA replication and virus assembly (Leung et al., 2008; Mackenzie 
et al., 1998). It is suggested that the NS2A protein inhibits the host antiviral interferon 
response (Liu et al., 2004, 2006).  
 The NS2B is also a small membrane-associated protein (Clum et al., 1997). The 
NS2B protein forms the complex with the NS3 protein, and plays a role as a cofactor of 
the NS3 protease activation (Arias et al., 1993; Falgout et al., 1991).  
 The NS3 protein is a large multifunctional protein, with several activities 
required for polyprotein processing and RNA replication. N-terminal region of the protein 
is the catalytic domain of the NS2B-NS3 serine protease complex, and C-terminal region 
contains RNA helicase and RNA-stimulated nucleoside triphosphatase activation domain 
(Chambers et al., 1990; Gorbalenya et al., 1989a, b; Li et al., 1999). Also, the NS3 
protease with the NS2B cofactor induces caspase 3 activation and mitochondria-mediated 
apoptosis (Yang et al., 2009). 
 The NS4A and the NS4B are small hydrophobic proteins. The NS4A protein co-
localizes with RNA replication complex, and plays an important role in RNA replication 
(Mackenzie et al., 1998). It is recently reported that the NS4A functions as a cofactor of 
the NS3 helicase activity (Shiryaev et al., 2009), and protects host cells from death and 
enhances virus replication by inducing autophagy of host cells (McLean et al., 2011). 
Both the NS4A and the NS4B associate with the negative modulation of the interferon 
response in host cells (Evans et al., 2007; Lin et al., 2008; Muñoz-Jordán et al., 2005). 
 The NS5 protein is a large, highly conserved, and multifunctional protein with 
methyltransferase and RNA dependent RNA polymerase (Chu et al., 1987). The 
methyltransferase domain on the N-terminal region of NS5 the protein is involved in 
 cap (Egloff et al., 2002).   
1.3. Epidemiology 
As described above, JEV is widely endemic in the Southeast Asia and Western 
Pacific regions (Mackenzie et al., 2001), with the annual incidence of the disease being 
approximately 50,000 cases and 10,000 deaths in humans (Erlanger et al., 2009). Recently, 
the number of incidence has been stable or declined dramatically in Japan, South Korea, 
Taiwan, China, Nepal, Sri Lanka, and Thailand due to the effective vaccination program 
with regular surveillance. In contrast, the epidemic activity in countries such as, India, 
Cambodia, Bangladesh, Indonesia, Laos, Myanmar, and Pakistan, where vaccination 
program or regular surveillance are not in place, has been increased in recent years 
(Erlanger et al., 2009).  
In Japan, although there were several thousand JE patients during the 1950s, JE 
cases in human decreased dramatically in the 1980s due to the vaccination program 
started in 1967 (IDSC, 2003). In recent two decades, annual JE cases in human are less 
than ten. From 2003 to 2008, total of 33 JE cases were reported in Japan and all cases 
occurred in the western part of Japan, especially in Kyushu and Shikoku districts (IDSC, 
2009). As well as human, since 1986, there has been no report of equine JE in Japan due 
to the effective vaccination program and improvement of hygiene around horses. 
However, one unvaccinated horse died from JE in Tottori Prefecture in 2003, and horses 
around the diseased horse also showed significant increase of antibodies against JEV 
during this endemic period (Yamanaka et al., 2006).  
Annual sero-survey in pigs as indicator of the JEV activity is performed by 
National Institute of Infectious Diseases in Japan by detecting HI antibodies against JEV. 
In recent years, the earliest detection of positive pigs has been around May in Okinawa 
and around July in the other parts of Japan. In 2008, JEV-positive pigs were detected in 
34 out of 35 prefectures, and more than 50% of pigs were seropositive for JEV in 24 
prefectures, mainly in western part of Japan (IDSC, 2009).   
Therefore, although the number of the JE cases has been decreased in both 
human and horses, there is still a risk of disease by JEV infection in Japan, if the 
immunization against JEV is not enough. 
1.4. Diseases and pathogenesis 
The incubation period of JEV after infection to human is about 5 to 15 days. The 
illness begins with 2 to 4 days prodromal phase of headache, fever, chills, anorexia, 
nausea, vomiting, dizziness and drowsiness. These symptoms are followed by the 
appearance of nuchal rigidity, photophobia, altered states of consciousness, 
hyperexcitability, and various objective neurological signs (Dickerson et al., 1952).  
Since there is no JEV-specific therapy, only supportive therapy is available. 
Although cerebral edema has been postulated to be an important factor in pathogenesis, 
control trial of high-dose corticosteroid therapy failed to show benefit in clinical outcome 
(Hoke et al., 1992). Anti-trypanosoma drug, suramin, showed a complete protection 
against experimental JEV infection in a mouse model (Swarup et al., 2008). In vitro
analysis using Vero cells showed that, a furanonaphthoquinone derivative, FNQ3, has 
some antiviral activity (Takegami et al., 1998). However, safety and in vivo effectiveness 
of these drugs remains unknown (Burke et al., 2001).  
In horses, the incubation period is 8 to 10 days. Symptoms are varied in severity 
of JE. Some horses have a transient fever, anorexia and lethargy, which last only for 2 or 
3 days and recover without any complication. Other horses develop encephalitis. In 
milder cases, the horse has a fluctuating fever and neurological signs that commonly 
include difficulty of swallowing, incoordination, transient neck rigidity, radial paralysis 
or impaired vision, and usually recover within a week. In severe cases, the horse has a 
high fever, aimless wandering, violent and demented behavior, occasional blindness, 
profuse sweating and muscle tremors, and these symptoms are often followed by collapse 
and death within 1 or 2 days. This severe case is uncommon that occurs in less than 5% 
of symptomatic horses (CFSPH, 2007; OIE, 2009)  
In pigs, JEV is usually characterized as a causative agent of reproductive disease, 
such as the birth of stillborn or mummified fetuses (OIE, 2009), and it is rare for infected 
pigs to become encephalitis (Nakamura et al., 1967). Most nonpregnant pigs are 
asymptomatic or experience only a transient febrile illness. Disturbances of 
spermatogenesis can cause temporal infertility in boars (CFSPH, 2007). 
1.5. Diagnosis 
In fatal cases, virus isolation and demonstration of viral antigen in brain tissue 
are feasible for a definitive diagnosis. Rapid diagnosis may be carried out by staining for 
antigen in mononuclear cells collected from cerebrospinal fluid (CSF) (Mathur et al., 
1990). From up to one third of patients on acute phase, virus may be isolated from their 
CSF, which is correlated with a poor prognosis. Serum antibody tests, such as the 
hemagglutination inhibition (HI), complement fixation (CF), and virus-neutralization 
(VN) tests, are also applicable for diagnosis of JEV infection. Cross-reactions with other 
flaviviruses, especially West Nile virus (WNV), may complicate the serologic diagnosis 
in place where various flaviviruses are endemic. Therefore, monoclonal epitope-blocking 
immunoassays may be used to identify JEV-specific antibody among patients in these 
areas (Burke et al., 1982a, b). 
1.6. Prevention and control 
The most effective way of controlling JEV is the use of vaccine. Vaccination of 
horses with formalin-inactivated vaccines was the first successful application and 
afforded significant protection during an epizootic in Japan in 1948 (Hoshi et al., 1948). 
The first inactivated vaccines for human was prepared in 1954, which was based on the 
formalin-inactivated strain Nakayama grown in adult mouse brain (Takaku et al., 1968). 
In 1972, live attenuated vaccines for use in pig was also licensed in Japan, which was a 
critical method to interrupting transmission and amplification of JEV, resulting in a 
prevention of human infections with JEV (Yoshida et al., 1981). After the successful 
vaccination program of JEV in Japan, the technology developed in Japan was transferred 
to other Asian countries. Vaccine manufacture was started in Taiwan, Korea, India, 
Thailand, Russia and Vietnam from 1960s to 1980s (Barrett et al., 1997). 
Republic of China, following the successful development of inactivated JEV vaccine in 
other Asian countries, an attenuated JE vaccine, SA14-14-2 was developed in 1988 (Xin 
et al., 1988). In Japan, due to the side effect, acute disseminated encephalomyelitis, of 
mouse brain-derived JE vaccine (Menge et al., 2005; Plesner et al., 1998), the strong 
recommendation of JE vaccination was halted in 2005 (Kurane et al., 2005; Okabe et al., 
2005). To dissolve the side-effect by mouse brain-derived JE vaccine, new Vero cell-
derived inactivated JE vaccine (Beijing-01 strain) was developed and licensed, and the 
recommendation of JE vaccination was resumed in 2009 (IDSC, 2009).  
Besides the vaccination of amplifiers or dead-end host, vector control is another 
way of prevention from JEV infection. As an environmental management for vector 
control, alternate wet and dry irrigation (AWDI) can substantially reduce vector breeding, 
along with saving water, increasing rice yields, and reducing methane emission (Keiser 
et al., 2005). However, an effective irrigation requires well-organized educational 
programs, sufficient water at specific times during the rice growing cycle, and an adequate 
infrastructure (Erlanger et al., 2009; Rajendran et al., 1995). As a chemical vector control, 
insecticides such as pyrethroids, organophosphates, and carbamates are used, which can 
break the transmission cycle of arbovirus in the short term. However, since JE vectors 
prefer irrigated rice fields that are often heavily exposed to pesticide selection pressure, 
rising levels of insecitide resistance have compromised the effectiveness of this vector 
control program (Erlanger et al., 2009; Karunaratne et al., 2000).  
1.7. Unknown facts 
In Japan, there is a question how JEV can spend during winter seasons. Although 
pigs are known as major amplifiers of JEV in summer season during June and October, 
they are unlikely to be a host of JEV in winter seasons, because they are shipped before 
6 months old. So far, there are several hypotheses how JEV is kept in winter seasons; 
carried from continents by migrating birds or mosquitoes, kept by wild animals, and kept 
by mosquitoes which pass the winter season. However, there is no clear answer to this 
question, yet. Furthermore, it is doubtful whether pig is only an amplifier in summer 
seasons. In the case of West Nile virus (WNV), birds are thought to be main amplifiers. 
However, previous studies on WNV show that experimentally infected chipmunks 
develop high level of viremia enough to infect vector mosquitoes (Platt et al., 2007), and 
persistent shedding of virus in urine up to 8 months among experimentally infected golden 
hamsters (Tesh et al., 2005). These facts show the possibility of amplifier for JEV other 
than pigs. Therefore, it is important to clarify these questions to understand the 
transmission cycle of JEV, and to prevent and control JEV and other flaviviruses.  
2. CHPATER 1 
Dogs, but not cats, are good sentinels for 
Japanese encephalitis virus infection 
2.1. ABSTRACT 
In this chapter, to assess the indirect risk of JEV infection to human, serosurvey 
of JEV in companion animals was performed. First, dogs and cats in Yamaguchi 
prefecture, in the western part of Japan, were examined, resulting that 17% (17 out of 
100) of dogs and 1% (3 out of 292) of cats were seropositive for JEV. Furthermore, I 
examined seroprevalence of dogs from throughout Japan, resulting that 25% (164 out of 
652) of dogs had VN antibodies against JEV. Dogs in northern part of Japan, Hokkaido 
(0%) and Tohoku (9%), showed significantly lower seroprevalence than other districts, 
while dogs in south-western part of Japan, Shikoku (61%) and Kyushu (47%) showed 
significantly higher seroprevalence than other districts. Interestingly, 8% (18 out of 222) 
of indoor-only family dogs and 21% (86 out 413) of dogs in urban/residential areas were 
seropositive, which indicate that the risk of JEV infection in human remain still high in 
Japan, especially in the south-western part. Dogs may be a good sentinel to assess the risk 
of JEV infection in residents, as they share their living spaces with human and are not 
vaccinated for JEV. 
2.2. INTRODUCTION 
As mentioned in GENERAL INTRODUCTION, annual serosurveys for 
antibodies to JEV in pigs, which are the main amplifiers of JEV, show high seropositivity 
in western part of Japan (Arai et al., 2008). Although this data indicates that JEV remains 
endemic in Japan and humans still possess high risk of JEV infection, it is discussed 
whether serosurveys of pigs accurately reflect risk of infection to humans because pig 
farms are apart from human society, urban/residential areas. Therefore, another method 
for monitoring JEV infection risk to humans in urban/residential areas is necessary. 
The serosurvey of cats and dogs were conducted for West Nile Virus (WNV) 
during epidemic infection in human in United States. The serum samples were screened 
by use of the plaques reduction VN test, and as the result, 26% of dogs and 9% of cats 
were seropositive in St Tammany Parish and the Slidell community, United States (Kile 
et al., 2005). Also, the serologic survey of juvenile dogs for WNV was conducted in 
Houston. Seroconversion in the serum samples were detected 6 weeks before the first 
reported human case (Resnick et al., 2008). These serologic surveys showed that dogs 
and cats may be useful sentinels for evidence of WNV, and since JEV is genetically close 
to WNV, dogs and cats may also be good sentinels for JEV. 
In this chapter, I conducted serosurvey of JEV in dogs and cats, which share 
living space with humans in order to discuss the risk of JEV infection in urban/residential 
areas, and to assess whether companion animals could be useful sentinels for JEV. 
2.3. MATERIALS AND METHODS 
2.3.1. Cells  
Vero cells (Vero 9013, JCRB number; JCRB9013), originated from African 
green monkey, were purchased from human science research resource bank (HSRRB, 
.) 
with 5% heat-inactivated fetal calf serum (FCS; Hyclone®, Canada), 1mM sodium 
pyruvate, 100U/ml of penicillin and 100µg/ml of streptomycin (GIBCO, U.S.A.) at 37°C 
in 5% CO2. Mosquito-originated C6/36 cells (JCRB number; IFO 50010) were cultured 
.) with 10% heat-
inactivated FCS, 100U/ml penicillin and 100µg/ml streptomycin at 28°C in 5% CO2. 
2.3.2. Virus 
JEV/sw/Chiba/88/2002, which was kindly provided by Dr. Tomohiko Takasaki 
(National Institute of infectious Diseases, Japan), was isolated from peripheral blood 
mononuclear cells of a healthy pig in 2002, and was genetically classified into genotype 
I (Nerome et al., 2007). The virus was propagated in C6/36 cells in DMEM with 2% FCS 
at 28°C and was stored at -80°C until use. 
2.3.3. Serum samples 
A total of 100 dog serum samples from 2006 to 2007 and 292 cat serum samples 
(215 samples from 1997 to 1999, 77 samples from 2004 to 2005) were collected from 
veterinary hospitals in Yamaguchi, and a total of 652 dog serum samples from November 
2006 to October 2007 were collected from veterinary hospitals throughout Japan. All sera 
were inactivated by incubation at 56°C for 30 min and then stored at -20°C until use.
2.3.4. Plaque assay for titration of viruses 
Viral infectivity was measured by plaque formation assay. Serially diluted 
viruses were inoculated onto Vero 9013 cells in a 6-well plates (Sumitomo Bakelite, 
Japan). After incubation for 90 min at 37°C in 5% CO2, the cells were washed twice with 
EMEM and overlaid with 0.8% agarose (Seaplaque agarose, FMC BioProducts, U.S.A.) 
in EMEM containing 5% FCS. The plates were then incubated at 37°C in 5% CO2 for 4 
days. The cells were fixed with 5% buffered formaldehyde for 1 hour, and the agarose 
layers were removed. After staining with crystal violet, plaques were counted.  
2.3.5. VN test 
To determine the presence of VN antibody against JEV in sera, 80% plaque 
reduction VN test was carried out according to the previous report (Ohno et al., 2009). 
For the first screening of JEV-positive sera, sera were diluted to 1:5 in EMEM containing 
2% FCS. To determine VN titer, sera were serially two-fold diluted in EMEM containing 
2% FCS. The diluted sera or medium alone were mixed with equal volumes of virus 
solution containing 100 PFU of JEV/sw/Chiba/88/2002 and then were incubated at 37°C 
for 90 min. After incubation, the mixtures were added to 6-well plates that were 
subconfluented with Vero 9013 cells and the plates were incubated at 37°C for 90 min, 
washed twice with EMEM and overlaid with 0.8% agarose in EMEM containing 5% FCS. 
The plates were then incubated at 37°C in 5% CO2 for 4 days. The cells were fixed with 
5% buffered formaldehyde for 1 hour, and the agarose layers were removed. After 
staining with crystal violet, plaques were counted. Sera that reduced number of plaques 
by more than 80% comparison with the mean number of plaques in control wells were 
considered as seropositive according to the previous report of WNV seroprevalence in 
cats and dogs (Kile et al., 2005). 
2.3.6. Statistical analysis 
To analyze the results statistically, chi-
were performed. The significant level was p < 0.05. 
2.4. RESULTS 
2.4.1 JEV infection to companion animals in Yamaguchi, Japan 
The seroprevalence of JEV in 100 dogs and 292 cats in veterinary hospitals in 
Yamaguchi, was examined by VN test. The result showed that 17% of dogs and 1% of 
cats were seropositive for JEV. The seropositivity in dogs was about 17-fold higher than 
that in cats. In addition, outdoor-only family dogs (38%) were about 4-fold more 
seropositive than indoor-only family dogs (10%) (p < 0.05). There were no significant 
difference between antibody prevalence in male (14%) and female (20%) dogs (p > 0.05) 
(Table 2-1). 
2.4.2 JEV infection to dogs throughout Japan 
 Serum samples from 652 dogs collected from every prefecture in Japan between 
2006 and 2007 were examined for seroprevalence of JEV. The results showed that 25% 
of dogs had VN antibodies against JEV. In Hokkaido and Tohoku districts, 0% and 9% of 
dogs, respectively, were seropositive. The seropositivities were significantly lower than 
in other districts (p < 0.05). In contrast, 61% and 47% of dogs in Shikoku and Kyushu 
districts, respectively, were seropositive. These levels were significantly higher than those 
in other districts with the other districts (p < 0.05). Seropositivity to JEV in Kanto (17%), 
Chubu (18%), Kinki (23%) and Chugoku (26%) districts did not show any significant 
difference (p > 0.05) (Table 2-2, Fig. 2-1). In addition, 45% of outdoor-only family dogs, 
and 8% of indoor-only family dogs were seropositive for JEV, thus confirming that 
outdoor-only family dogs were 5.5-fold more likely to be seropositive than indoor-only 
family dogs (p < 0.05). Especially, 75% and 77% of outdoor-only family dogs were 
seropositive in Shikoku and Kyushu districts, respectively. Regarding the areas of 
residence, 21% of dogs in urban/residential areas and 44% of dogs in rural area were 
seropositive; the results for rural areas were significantly higher than urban/residential 
areas (Table 2-2). There was no significant correlation between ages of dogs and 
seopositivities to JEV (data not shown). 
2.5. DISCUSSION 
In Yamaguchi, seropositivity for JEV was significantly higher among dogs 
(17%) than cats (1%). From 1954 to 1955, similar results were reported: 55% of dogs and 
10% of cats were seropositive for JEV (Nakamura et al., 1967). In addition, 26% of dogs 
and 9% of cats in Louisiana, and 5% of dogs and no cats in New York were seropositive 
for West Nile virus (WNV) (Kile et al., 2005; Resnick et al., 2008). As dogs appear to be 
more sensitive indicators of several flavivirus infections than cats, I conducted a 
serosurvey of dogs throughout Japan.  
A previous reports on host feeding pattern of JEV and WNV vectors showed that 
the vectors, Culex spp, feed on various mammals, including dogs, cats, and humans and 
they tend to feed on dogs more than cats and humans (Mitchell et al., 1973; Molaei et al., 
2007). These reports are consistent with our results that dogs showed higher seropositivity 
than cats and humans, and also indicate that some JEV vectors do accidentally feed on 
humans. 
The nationwide serosurvey indicated that JEV prevalence is significantly lower 
in the Hokkaido and Tohoku districts and significantly higher in the Kyushu and Shikoku 
districts (Figure 2-1). The results of annual serosurveys in pigs have also shown that pigs 
in the western part of Japan tend to have higher seropositivity rates for JEV than those in 
the northern part. In addition, the number of human JE cases from 2005 to 2007 in Japan 
was 24, most of which occurred in the western part of Japan (IDSC, 2009). This is 
consistent with our data, suggesting that serosurveys in dogs accurately reflect JEV 
infection risk to humans in Japan. 
In our study, 45% of outdoor-only family dogs were seropositive. A previous 
study on WNV showed that 69% of outdoor-only family dogs were seropositive during 
an epidemic of WNV infection in humans (Kile et al., 2005). A previous serosurvey of 
JEV in Tokyo in Kanto district between 1954 and 1955 showed that 49% of stray dogs 
were seropositive (Nakamura, 1967). Both study results are similar to results in this study, 
indicating that the risk of JEV infection remains high in Japan, particularly in the western 
part of Japan. In addition, the confirmation of seropositivity among indoor-only family 
dogs (8%) indicates that JEV-infected mosquitoes may enter houses and that infants and 
elderly individuals, who tend to go outside less frequently, might be also at risk of JEV 
infection. 
The seropositivity in rural areas (44%) was significantly higher than in 
urban/residential areas. This suggests that the existence of pig farms and rice paddies in 
rural areas is associated with environmental JEV levels. However, the relatively high 
seropositivity in urban/residential areas (21%), suggests that JEV infection risk in humans 
remains high even in these areas, where there are not so many pig farms and rice paddies. 
As pigs are kept apart from human society, serosurveys of pigs in urban/residential areas 
are limited. Therefore, dogs, which are found in all areas of Japan, may be better sentinels 
for JEV infection in these areas. However, it is not clear whether dogs become viremia 
after JEV infection, how long anti-JEV antibodies last and so on. Therefore, I conducted 
experimental infection of JEV against dogs in CHAPTER 2.  
In conclusion, this study found that the risk of JEV infection remains high, even 
in urban/residential areas, when dogs were used as sentinels. Therefore, it is 
recommended that annual JEV surveillance should be carried out in pigs in Japan and that 
dogs should be surveyed every several years to assess the risk of JEV infection in humans 
in urban/residential areas. 
2.6. LEGEND FOR FIGURE 
Figure 2-1. Geographical distribution of seropositivity for JEV among dogs from 2006 
to 2007. Japan was divided into 9 districts: Okinawa, Kyushu, Shikoku, Chugoku, Kinki, 
Chubu, Kanto, Tohoku and Hokkaido. The numbers in parenthesis beside each pie graph 
indicate the number of examined samples. The size of each circle indicates the number of 
samples. Black and white parts of the pie charts show the proportion of seropositive and 
seronegative dogs, respectively. 
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Figure 2-1 Geographical distribution of seropositivity for JEV among dogs from 2006 to 2007. 
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Table 2-1. Seroprevalence of JEV in dogs and cats in Yamaguchi 
Dogs Cats Indoor Outdoor Both or unknown Total 
Number of
examined animals 58 21 21 100 292 
Number of
JEV-positive animals 6 8 3 17 3 
% of positive animals 10 38 14 17 1 
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Table 2-2. Seroprevalence of JEV in dogs throughout Japan 
a The following demographic information was recorded by questionnaire to owners: housing environment (indoor, outdoor, or both), and the 
location of the house at which the dog is kept (urban/residential or rural).  
Where dog staysa  Areaa
Total 
Indoor Outdoor Both or Unknown 
Urban
/Residential Rural Unknown 
Number of
examined dogs 222 234 196  413 147 92 652 
Number of JEV-positive 
dogs 18 105 41  86 65 13 164 
% of positive dogs 8 45 21  21 44 14 25 
3. CHAPTER 2 
Experimental infection to dogs with Japanese encephalitis virus 
3.1. ABSTRACT
In this chapter, three dogs were experimentally infected with a high dose of JEV. 
Neither clinical sign nor abnormal result of blood examination except for C-reactive 
protein was observed in all dogs. VN titers rapidly increased at 1:1280 (No.1), 1:640 
(No.2) and 1:320 (No.3), and were kept at the same level at least for 70 days after 
challenge. Virus isolation and RT-PCR from sera or peripheral blood mononuclear cells 
showed that any live virus or viral RNA was not detected in blood. In conclusion, dogs 
may be safe and useful sentinels to survey the human risk of JEV infection in urban areas, 
because any viremia and clinical sign are not developed in dogs after JEV infection. 
3.2. INTRODUCTION
Since dogs, but not pigs, live together with their owners, seroprevalence of JEV 
in dogs indicate the human risk more strongly than that in pigs. In CHAPTER 1, 
serosurvey on JEV in Japan showed that 25% of dogs had VN antibodies against JEV. 
Furthermore, higher seropositivities were detected in the western part of Japan, Kyushu 
(47%) and Shikoku (61%) districts (CHAPTER 1; Shimoda et al., 2010). However, 
duration of anti-JEV antibodies and clinical symptoms after JEV infection in dogs still 
remain unknown. Furthermore, some canids were reported with encephalitis and 
myocarditis possibly associated with WNV, which belongs to Japanese encephalitis 
serocomplex (Cannon et al., 2006; Lichtensteiger et al., 2003; Read et al., 2005; Schwab 
et al., 2006).  
In this chapter, dogs were experimentally infected with JEV to examine the 
clinical symptoms and the duration of anti-JEV antibodies in dogs. 
3.3. MATERIALS AND METHODS 
3.3.1. Animal experiments 
Three female beagles (2 months old) without JEV antibody were purchased from 
NARC and were intraperitoneally and subcutaneously inoculated with 0.5ml of viral 
solution containing 5 x 106 plaque-forming units (PFU) of JaOH0566. JaOH0566 strain 
was isolated from JE patient in 1966 and was kindly provided by Dr. Ishikawa (Biken, 
Kagawa, Japan). Clinical signs were observed and body weight and temperature were 
measured every day. Blood samples were collected on day 0 to 14, 17, 21, 24, 28, 35, 42, 
49, 56, 63, 70, and 77 postchallenge. The animal experiments were approved by Animal 
Research Ethics Board of Faculty of Agriculture, Yamaguchi University. 
3.3.2. Sample treatments 
Peripheral blood samples were transferred into untreated and EDTA-treated 
evacuated tubes (BD vacutainer; Becton, Dickson, and Compane, U.S.A.). Serum 
samples were separated from untreated whole blood by centrifugation at 3,500 rpm for 
15min at 4°C and stocked at -80°C until use. Peripheral blood mononuclear cells (PBMC) 
were separated from 2ml of EDTA-treated whole blood mixed with 2ml of RPMI1640 
medium (GIBCO, U.S.A.) by layering over 2ml of LymphoprepTM (Axis-Sheild, Norway) 
and centrifuging at 800 g for 45min at room temperature. Isolated PBMC was then 
washed with RPMI1640, resuspended in 1ml of Cellbanker (Nippon Zenyaku Kogyo, 
Japan) and stocked at -80°C until use. Blood smears were prepared from a drop of EDTA-
treated blood, dried in air, and stained with Hemacolor (Merck, Germany). The slides 
were examined under light microscopy, and 300 white blood cells were counted. Each 
leukocyte was assigned to one of the following categories; lymphocytes, monocytes, 
segmented neutrophils, band neutrophils, eosinophils, basophils and other cells. 
Complete blood count (CBC), excluding hematocrit (Ht) and packed cell volume (PCV) 
were measured using Sysmex KX-21 (Sysmex, Japan) and Ht and PCV were measured 
by centrifugation in hematocrit capillary. Creatine phosphokinase (CPK), creatinine 
(CRE), blood urea nitrogen (BUN), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), glutamate oxaloacetate transaminase (GOT), gamma-glutamyl 
transpeptidase (GGT) were measured using DRI-CHEM 7000V (Fujifilm, Japan). C-
reactive protein (CRP) was measured by Laser CRP-2 (Arrows, Japan).  
3.3.3. Cells 
African green monkey-originated Vero9013 cells (JCRB number; JCRB9013) 
and mosquito-originated C6/36 cells (JCRB number; IFO 50010) were used in this study. 
The condition of culture media are the same as described in CHAPTER 1.  
3.3.4. Viruses 
Human-derived JaOH0566 (genotype III) and swine-derived 
JEV/sw/Chiba/88/2002 (genotype I) were used in this study. Human-derived JaOH0566 
was isolated in 1966 from brain of JE patient (Shah et al., 2006). The propagation of these 
viruses were performed the same as described in CHAPTER 1.  
3.3.5. Plaque assay for titration of viruses 
Viral infectivity was measured by plaque formation assay described in 
CHAPTER 1.  
3.3.6. VN test 
The presence of VN antibody against JEV in sera was determined by 80% plaque 
reduction VN test described in CHAPTER 1.  
3.3.7. Virus isolation 
Serially three-fold diluted PBMC or serum samples were incubated with 
Vero9013 or C6/36 cells in a 96-well plates at 37°C. Cytopathic effect (CPE) were 
monitored and if CPE was not found, the cells were passaged. After fifth passages, virus 
isolation was judged. Three days old suckling mice were intracerebrally inoculated with 
20 l of mixed sera and the clinical sign was observed every day. 
3.3.8. Detection of viral RNA 
Total RNA was extracted from sera using QIAamp viral RNA mini kit (Qiagen, 
U.S.A.). Then, RT-PCR was carried out using one-step RT-PCR kit (Qiagen, U.S.A.) with 
-GGA ACA GCA TGC AAA TCG AAG- -ACC 
AGA AGG CCC AGC TGA AAA- -PCR products were analyzed by 
electrophoresis in 1.5% agarose gel. It was checked that this RT-PCR could detect 0.23 
PFU of JEV in one reaction. 
3.3.9. Statistical analysis 
To analyze the results statistically, chi- probability tests 
were performed. The significant level was p < 0.05. 
3.4. RESULTS 
3.4.1. Clinical signs and blood tests 
While no clinical signs or increase in body temperature were observed during 
the observation period, transient decreases in body weight were observed on day 2 
postinfection (dogs No. 1 and No. 2) and from day 1 to 3 postinfection (dog No.3) (Figure 
3-1). Among the various blood parameters assayed, including a CBC and biochemical 
tests, only C-reactive protein (CRP; an index of inflammation) levels in sera were 
abnormally high. The CRP levels reached 2.35 mg/dl (dog No.1 - day 2), 5.6 mg/dl (dog 
No.2  day 1) and 1.05 mg/dl (dog No.3  day 2) before recovering to less than 1.0 mg/dl 
by 6 days after challenge (Figure 3-2). 
3.4.2. VN titers 
VN titers of sera collected from experimentally JEV-infected dogs against 
JaOH0566 were measured. The results showed that until 21 days after challenge in dogs 
No.1 and No.2, and 28 days in dog No.3, VN titers kept increasing before being 
maintained at similar levels for 70 days after challenge (Table 3-1). Interestingly, the sera 
(day 28 post infection) of all animals exhibited cross-VN activity to 
JEV/sw/Chiba/88/2002, which belongs to genotype I (data not shown). 
3.4.3. Virus isolation and detection 
To examine the presence of JEV in blood, sera and peripheral blood mononuclear 
cells collected on day 1 to 3, 7, 10, 14 and 17 postinfection were inoculated onto Vero9013 
cells, and only sera were intracerebrally inoculated to suckling mice. Furthermore, sera 
collected on day 1 to 3 were examined by RT-PCR for detection of JEV RNA. As a result, 
neither the virus nor the viral genome was detected in blood by these methods (data not 
shown). 
3.5. DISCUSSION 
Annual serological survey for JEV was performed among pigs in Japan, and 
showed high seropositivities, especially in western part of Japan (Arai et al., 2008). 
Furthermore, previous study about experimental JEV infection against pigs showed that 
VN titers of 1:20 to 1:80 were detected in all pigs on 14 days after challenge, and were 
kept at the detectable level until 47 days after challenge, with the exception of one pig 
(Williams et al., 2001). In our study, VN titers of every infected dog were kept at the same 
level at least for 70 days after challenge. These result suggested that dogs develop VN 
antibodies as well as pigs, and its duration period is long. In addition, the result of 
serological survey on JEV among dogs in CHAPTER 1 showed higher seropositivities in 
western part of Japan, which is consistent with the results of annual serological surveys 
among pigs.  
In the previous study on WNV, although experimentally infected dogs did not 
show any clinical symptoms, viremia was detected in all infected dogs (Austgen et al., 
2004). In addition, as described above, some canids were reported with encephalitis and 
myocarditis possibly associated with WNV (Cannon et al., 2006; Lichtensteiger et al., 
2003; Read et al., 2005; Schwab et al., 2006). In contrast, no clinical symptom was 
observed and no viremia or JEV RNA was detected from blood samples of JEV infected 
dogs in this study. Furthermore, even during JEV was endemic in Japan, no JE cases in 
domestic animals, like dogs or cats, were reported (Nakamura et al., 1967). Although a 
previous report show that dogs develop encephalitis and viremia after experimental 
infection, they were all inoculated intracerebrally, which is not natural infection route of 
JEV (Hotta et al., 1964). These facts suggest that JEV infected dogs are unlikely to 
develop viremia via natural infection route, and a risk of human JEV infection from dogs 
is extremely low. 
Previous study among dogs showed measurement of CRP can be a useful marker 
of inflammation and ideal cut-off value is 1.0mg/dl (Onishi et al., 2000). In this study, 
although clinical symptoms were not observed in any dogs, abnormal increase of CRP 
was observed in all dogs. It indicates that some inflammation had occurred in these dogs 
after inoculation of JEV, and suggests JEV infection might cause inflammation. 
The ideal sentinels for serologic survey would be susceptible to infection, 
survive the infection, develop detectable antibodies, possess no risk of infection to 
handlers, and never develop a high enough level of viremia to infect vector mosquitoes 
(Resnick et al., 2008). The serological survey in CHAPTER 1 (Shimoda et al., 2010) and 
this study showed that dogs may be useful and safe sentinel to identify a risk of human 
infection, especially in cities and indoors.
3.6. LEGENDS FOR FIGURES 
Figure 3-1. Body weight of JEV experimentally infected dogs. X-axis indicates the 
number of days after infection. Y-axis indicates the relative body weight of JEV infected 
dogs. The data were expressed as relative values, with Day 0 of each dogs being 100.  
Figure 3-2. The increase of CRP level in serum of experimentally JEV infected dogs. X-
axis indicates the number of days after infection. Y-axis indicates the quantity of CRP in 




Table 3-1. VN titers in JEV-infected dogs 
Dogs 
Days after challenge 
0 7 14 21 28 35 42 56 70
No.1 <1:10 1:160 1:160 1:1280 1:640 1:1280 1:640 1:640 1:640 
No.2 <1:10 1:320 1:320 1:640 1:640 1:640 1:640 1:320 1:320 
No.3 <1:10 1:80 1:40 1:160 1:320 1:320 1:160 1:160 1:80 
4. CHAPTER 3 
Development and application of an indirect enzyme-linked immunosorbent assay 
for serological survey of Japanese encephalitis virus infection in dogs 
4.1. ABSTRACT 
Although I described in the previous chapter that dogs are good sentinels to 
assess the risk of JEV infection in humans, a VN test has been the only method available 
for measuring JEV antibody levels in dogs. In this chapter, an indirect enzyme-linked 
immunosorbent assay (ELISA) for a serological survey of JEV infection in dogs, using 
purified viral particles as an antigen, was developed. In dogs inoculated experimentally 
with JEV, ELISA detected anti-JEV IgM at 3 days after infection, with IgM levels peaking 
at 7 days after infection. Anti-JEV IgG were detected at 14 days after infection and peaked 
on 21-28 days after infection. VN titers did likely correlate with the sum of anti-JEV IgM 
and IgG measured by the ELISA. To test the utility of the new assay, the seroprevalence 
of JEV infection among 102 dogs in Kyushu, Japan, was examined by both IgG ELISA 
and VN test. The correlation coefficient between IgG ELISA and VN test was 0.813 
(p<0.001); comparison of IgG ELISA and VN test revealed a sensitivity and specificity 
of 82% and 98%, respectively. IgG ELISA was used to survey dogs in Bangkok, Thailand, 
with the results showing that 51% of these dogs were seropositive for JEV. These data 
suggest that even in the capital city of Thailand, the risk of infection with flaviviruses, 
including JEV, remains high. This indirect IgG ELISA for dogs is a useful and simple 
method to assess the risk of JEV infection to humans. 
4.2. INTRODUCTION  
In Thailand, 1,500 to 2,500 JE cases had been reported annually throughout the 
1970s and the 1980s (Olsen et al., 2010). In contrast, between 2005 and 2010, the annual 
number of encephalitis cases in Thailand ranged from 322 to 431, including 36 to 78 
confirmed JE cases per year (Thailand Ministry of Public Health). This dramatic 
reduction in the number of JE cases over the past 20 years has been the result of an 
effective human vaccination program by the Thailand Ministry of Public Health. However, 
a recent (2009) serological survey showed that 39% of pigs are seropositive for JEV in 
Thailand; the seroprevalence of JEV was especially high (67%) in pigs in Chiang Mai 
province, which includes the second biggest city of Thailand (Prompiram et al., 2011). In 
addition, the number of JE cases in Thailand still exceeds those in other vaccine-
controlled countries, such as Japan and Korea (Erlanger et al., 2009). However, recent 
human risk of JEV infection in the capital city, Bangkok, remains unknown.    
Serological tests such as VN test and hemagglutination inhibition (HI) have been 
the primary assays used to detect JEV-specific antibodies in serum (Anderson et al., 2011, 
Chiou et al., 2007, Mall et al., 1995, Ting et al., 2004, Watanabe et al., 2008). The HI 
requires a large volume of serum, while the VN test requires a special facility (e.g., 
biosafety level-2 or -3) and a high level of technical skill. In contrast, enzyme-linked 
immunosorbent assay (ELISA) does not require the use of live JEV, and the procedure is 
simple and requires only a small amount of sample. Other laboratories have reported the 
use of indirect IgG ELISA for JEV serological surveys among pigs and bats (Cui et al., 
2008, Hamano et al., 2007, Nidaira et al., 2007, Xinglin et al., 2005, Yang et al., 2006).  
In the previous chapters, I demonstrated the utility of dogs as sentinels for JEV 
infection to human. Therefore, in this chapter, an indirect ELISA to detect JEV antibodies 
in dogs was developed using sera of dogs infected experimentally and domestic dogs in 
Kyushu and Hokkaido, Japan. The test was then applied for a serological survey of dogs 
in Thailand to assess the risk of human infection with flaviviruses including JEV. 
4.3. MATERIALS AND METHODS 
4.3.1. Cells 
African green monkey-originated Vero9013 cells (JCRB number; JCRB9013) 
and mosquito-originated C6/36 cells (JCRB number; IFO 50010) were used in this study. 
The condition of culture media are the same as described in CHAPTER 1. 
4.3.2. Virus 
Swine-derived JEV/sw/Chiba/88/2002 (genotype I) were used in this study. The 
propagation of this virus was performed as described in CHAPTER 1. 
4.3.3. Dog serum samples 
Sera of dogs infected experimentally with JEV used in this study were 
sequentially collected and stored at -80 °C in CHAPTER 2 (Shimoda et al., 2011).  
For the serological survey, a total of 183 family dog sera were collected from 
domestic dogs in Kyushu and Hokkaido districts, Japan, and Bangkok, Thailand. These 
samples were collected from veterinary hospitals in Japan, or by visiting the owners of 
the examined dogs in Thailand. All owners were informed of the research objectives 
before sampling and data collection. To classify the dogs examined in this study, the 
owners also were asked to provide data about the sex, age, breed, and housing of their 
dogs. Note that all sera used for the VN test were inactivated by incubation at 56 °C for 
30 min to prevent the inactivation of JEV by complement in serum samples, and then 
stored at -20 °C until use.
4.3.4. VN test 
The presence of VN antibody against JEV in sera was determined by 80% plaque 
reduction VN test described in CHAPTER 1.  
4.3.5. ELISA 
For ELISA, inactivated JEV originating from the Beijing 01 strain was selected 
as the antigen. This strain had been propagated in Vero cells, inactivated with 
formaldehyde, and purified by ultracentrifugation, and the product was intended for use 
as a vaccine antigen in humans. The inactivated JEV was diluted to 5 
adsorption buffer (0.05 M carbonate-bicarbonate buffer, pH 9.6), and distributed at 100 
-well microplates (Maxisorp; Nunc, Roskilde, Denmark). Control wells 
received an equivalent volume of adsorption buffer without antigen. After incubation at 
37 °C for 2 hrs, plates were placed at 4 °C overnight. The wells were washed three times 
with phosphate-buffered saline (PBS) containing 0.05% Tween20 (PBS-T) and then 
action V; Sigma, 
St. Louis, MO, U.S.A.) in PBS at 37 °C for 30 min. Test sera were diluted with PBS-T 
containing 10% FCS. Wells were washed three times with PBS-T, and then diluted sera 
were added to duplicate wells, and plates were incubated at 37 °C for 30 min. Next, the 
wells were washed three times with PBS-
peroxidase-conjugated sheep anti-dog IgG or goat anti-dog IgM antibody (Bethyl 
Laboratories, Montgomery, TX, U.S.A.) at 37 °C for 30 min. Following washing three 
times with PBS- -Rad, Hercules, CA, 
U.S.A.) was added to each well. After incubation at room temperature for 30 min, the 
ch well. The 
absorbance was measured by a spectrophotometer (Bio-Rad) with a 405-nm filter. All 
results were corrected by the value of the non-antigen control.  
4.3.6. Optimization of concentration of ELISA antigen 
 The optimal concentration of the antigen was determined by cross-titration using 
the serially diluted antigen and the serially diluted serum from one mouse infected with 
JEV as the primary antibody. Based on the results of this preliminary study, an optimal 
antigen concentration of 5 µg/ml was selected (data not shown). 
4.3.7. Statistical analysis 
Chi-square test was performed to assess statistically the seroprevalence of JEV 
determine the correlation between VN test and IgG ELISA. p values of < 0.05 were 
considered statistically significant. 
4.4. RESULTS
4.4.1. Optimization of dilution of dog sera 
The optimal serum dilution was determined using sera collected from three dogs 
infected experimentally with JEV. IgG ELISA was carried out using sera diluted to 1:100 
and 1:500. The observed increases of JEV antibody after JEV challenge were consistent 
with the pattern seen by the VN test. Using 1:100 diluted serum, the OD value of IgG 
ELISA reached over 3.500 (the limit of detection) after day 14 in dogs No.1 and No.2 
(data not shown). On the other hand, absorbance exceeded 3.500 only after day 21 in dog 
No.1 and on day 28 in dog No.2 using 1:500 diluted sera (Figure 4-1). In addition, in dog 
No.3, the highest absorbance in 1:500 diluted sera was 2.270 on day 28. Therefore, to 
avoid false-positives and to examine the correlation between the absorbance of IgG 
ELISA and VN titers, a dilution of dog sera of 1:500 was selected for subsequent phases 
of this study. 
4.4.2. Determination of cut-off value 
 For any serological surveys, determination of the cut-off value is important. To 
determine the cut-off value, IgG ELISA was performed using 5 µg/ml of the JEV antigen 
and 1:500 diluted dog sera as the primary antibody. Eleven dog sera collected in Hokkaido, 
Japan, where there was no evidence of the prevalence of JEV in dogs (Shimoda et al., 
2010), were examined using IgG ELISA. The absorbance values obtained from these 11 
specimens ranged from 0.013 to 0.200. The mean IgG ELISA value was 0.052 with a 
standard deviation (S.D.) of 0.053 (data not shown). The mean value plus 3 S.D. (a value 
of 0.211) was selected as the cut-off value between positive and negative results in this 
study.   
4.4.3. Comparison of antibody response in dogs infected experimentally 
 In dogs infected experimentally with JEV, anti-JEV IgM was detected on day 3, 
peaked on day 7, and then gradually decreased. On the other hand, anti-JEV IgG increased 
on day 7 and peaked on day 21-28. For comparison, VN titers reached the first peak on 
day 7, and then started to increase again on day 14. Therefore, it is inferred that the titer 
detected by VN test corresponds to the sum of IgG and IgM concentrations (Figure 4-1).  
4.4.4. Specificity and sensitivity of IgG ELISA 
To investigate the specificity and sensitivity of IgG ELISA, 102 serum samples 
collected from dogs in Kyushu, Japan, were examined by both IgG ELISA and VN test. 
Of 49 serum samples judged positive by VN test, 40 and nine were positive and negative 
in the IgG ELISA, respectively; of 53 serum samples judged negative by VN test, only 
one was positive in the IgG ELISA (Table 4-1, Figure 4-2). Thus, in comparison with the 
results in VN test, the sensitivity and specificity of IgG ELISA were 82% and 98%, 
respectively. The correlation coefficient between IgG ELISA and VN test was 0.813 
(n=102, p<0.001). These results indicated that the result of IgG ELISA showed significant 
correlation with that of VN test.  
4.4.5. Seroprevalence of flaviviruses, including JEV, among dogs in Thailand 
To survey JEV infection among dogs in Bangkok, Thailand, 70 serum samples 
were examined by IgG ELISA, revealing that 36 out of 70 dogs (51%) were seropositive 
for JEV. The seroprevalence among older dogs (>3 yrs) tended to be higher than that 
among young dogs (3 yrs and under), but no significant difference was observed. In 
addition, 29 out of 44 (66%) dogs which kept outside (group A) were seropositive for 
JEV; in contrast, all dogs which are kept inside (group B) were seronegative (Table 4-2). 
The serum samples from dogs in Thailand were also screened using IgM ELISA, but the 
resulting absorbances were less than 0.3 (data not shown). 
4.5. DISCUSSION 
Previous studies in CHAPTER 1 and CHAPTER 2 showed that dogs are good 
sentinels to assess the risk of human infection with JEV, given that dogs share their life 
space with humans, are not vaccinated against JEV, do not display symptoms when 
infected, do not serve as amplifiers for JEV, and maintain VN titers for long periods after 
infection (Shimoda et al., 2010, 2011). These previous studies indicated that the VN test 
was a suitable method for serological surveys of JEV infection in dogs, but some sera, 
especially sera from wild animals, nonspecifically inhibited JEV infection in the VN test. 
Therefore, although surveys in humans typically employed a 50% plaque reduction assay, 
serological surveys in wild and companion animals were performed using an 80% plaque 
reduction assay (Ohno et al., 2009, Shimoda et al., 2010). In addition, the VN test is time-
consuming and requires a special facility. Therefore, other methods for the detection of 
JEV antibodies are desirable. In this study, indirect ELISA was developed to detect 
immunoglobulin for JEV in dogs, and the assay was applied in a serological survey on 
JEV infection to assess the risk of JEV infection in humans. 
A preliminary ELISA study (using sera from dogs infected experimentally with 
JEV) tested the use of an unpurified extract from Vero cells infected with 
JEV/sw/Chiba/88/2002 as the ELISA antigen. This extract yielded lower absorbances 
than those seen with inactivated JEV antigen (data not shown). Therefore, inactivated 
JEV was selected as the ELISA antigen for the present study. This inactivated JEV antigen 
corresponds to the JEV vaccine that has been used in Japan since 2009, and is derived 
from the Beijing 01 strain (JEV genotype III) that has been propagated in Vero cells, 
inactivated with formaldehyde, and purified by ultracentrifugation. 
Thus, in the present study, different viruses, Beijing 01 and 
JEV/sw/Chiba/88/2002, were used in ELISA and VN test, respectively. To avoid non-
specific reaction in ELISA, the vaccine for human use originated from Beijing 01 was 
selected, because the vaccine is, to our knowledge, the most purified JEV reagents 
available. For VN test, JEV/sw/Chiba/88/2002 routinely used in our laboratory (Ohno et 
al., 2009; Shimoda et al., 2010, 2011) was selected, because the plaques formed by the 
virus are large and clear. VN test using this strain could detect JEV antibodies in various 
animal species, including dogs, raccoons, wild boars, and raccoon dogs (Ohno et al., 
2009; Shimoda et al., 2010). In addition, some reports described that antibodies to JEV 
are cross-reactive among various JEV strains by VN test (Kitano, 1989; Liu et al., 2011). 
Therefore, it seems that our ELISA and VN test can detect a broad range of JEV antibody.  
Sensitivity and specificity of IgG ELISA, as well as correlation with VN test, 
were determined using domestic dogs in Kyushu, Japan, where there is no evidence of 
the prevalence of other flaviviruses. Absorbances in the IgG ELISA significantly 
correlated with VN titers (0.813; n=102, p<0.001), suggesting that the IgG ELISA is 
suitable for detection of JEV antibodies in dogs. Sensitivity (82%) of IgG ELISA in this 
study was not so high, as nine dogs that were seropositive by VN test were seronegative 
by IgG ELISA. Since sensitivity may have been decreased due to the use of highly diluted 
sera (1:500), these nine serum samples with inconsistent results were examined at higher 
serum concentrations (1:10, 1:20, 1:40, and 1:80). The results showed that significant 
increases of IgG ELISA values were obtained in 5 out of 9 samples (data not shown), 
suggesting these 5 dogs might be seropositive for JEV. In development of this IgG ELISA, 
the specificity was the first priority for avoiding false-positives. Therefore, 1:500 
dilutions of sera were used as the primary antibody, providing reduced background 
(compared to 1:100 dilutions) and increased specificity (Fig.1 and 2).  
In Thailand, only a few surveys for JEV infection have been reported recently 
(Olsen et al., 2010, Prompiram et al., 2011). In particular, the risk of human infection 
with JEV in the capital city, Bangkok, remains unknown. In this study, a serological 
survey of JEV among dogs in Bangkok showed that 66% of dogs belonging to group A 
possessed antibodies to JEV, while JEV antibodies were not detected in any exclusively 
dogs belonging to group B. In Japan, the seroporevalence of dogs belonging to group A 
(45%) was 5.5-fold higher than that of dogs belonging to group B (Shimoda et al., 2010). 
These data suggest that the risk of human infection with JEV in Bangkok may be similar 
to or even higher than that in Japan.  
Some inconsistent results between IgG ELISA and VN test also were observed 
in dogs in Thailand, as one of the putatively seronegative dogs by VN test yielded a high 
absorbance (of 2.084) by IgG ELISA (data not shown). It is hypothesized that this dog 
was infected with another flavivirus, such as dengue virus (DENV), which is endemic in 
Thailand (Hemungkorn et al., 2007). Upon testing by indirect IgG ELISA (using 
DENGUE IgG INDIRECT ELISA (Panbio, Queensland, Australia) only as the DENV 
antigen), this serum sample displayed high ELISA titer against DENV (data not shown). 
Thus, this dog may have been infected with DENV.  
ELISA of sera from dogs infected experimentally with JEV showed that anti-
JEV IgM appeared earlier than IgG and then rapidly disappeared (Fig.1), which is 
consistent with the results of a previous study on experimental infection of JEV against 
pigs (Ohkubo et al., 1984). These data suggest that the detection of anti-JEV IgM in this 
assay indicates recent infection with JEV. In the survey of Thai dogs, no dog possessed 
significant levels of anti-JEV IgM, suggesting that infection with JEV had occurred more 
than 2-3 weeks before sampling. However, the values of the indirect ELISA for detection 
of anti-JEV IgM are not quantitative, since the binding strength of IgM is weaker than 
that of IgG, and the absorbance of anti-JEV IgM also may depend on the amount of anti-
JEV IgG. The development of an IgM-capture ELISA, which has been used previously 
in serological surveys of humans and pigs (Hamano et al., 2007, Jacobson et al., 2007), 
might be required for the assessment of recent JEV infection.  
In conclusion, an indirect ELISA was described for the detection of JEV 
antibodies in dogs; this assay allowed us to examine a large number of samples at once 
and to assess the levels of anti-JEV immunoglobulins in canine specimens quantitatively. 
This method is expected to facilitate the assessment of the human risk of JEV infection. 
4.6. LEGENDS FOR FIGURES  
Figure 4-1. Enzyme-linked immunosorbent assay (ELISA) values using 1:500 diluted 
sera and VN titers in dogs infected experimentally with Japanese encephalitis virus (JEV). 
Absorbances in IgG (closed circle) and IgM (closed triangle) ELISA are compared with 
VN titers (open diamond) (Shimoda et al., 2011). 
Figure 4-2. Comparison of IgG ELISA values using 1:500 diluted sera and VN titers 
among dogs in Kyushu, Japan. Absorbances in IgG ELISA and VN titers are plotted. 
Closed circles, positive by both IgG ELISA and VN test; closed squares, negative by both 
IgG ELISA and VN test; open circles, positive only by VN test; open squares, positive 









Positive 40 1 41 
Negative 9 52 61 
Total 49 53 102 
57 
Table 4-2. Seroprevalence of JEV by IgG-ELISA among dog population in Bangkok, Thailand  
 Housing  Age (year)  
Total 
 Indoor Outdoor Both  0-3 4-6 7-  
No. of examined dogs 9 44 17  13 33 24  70 
No. of JEV-positive dogs 0 29 7  5 17 14  36 
% of JEV-positive dogs 0 66 41  38 52 58  51 
5. CHAPTER 4 
Seroprevalence of Japanese encephalitis virus infection 
in Japanese macaques (Macaca fuscata) in Japan 
5.1. ABSTRACT  
In this chapter, a serosurvey of JEV in Japanese macaques (Macaca fuscata) 
reared in Aichi Prefecture was performed using purified JEV as an antigen for ELISA. 
The results showed that 146 of 332 monkeys (44.0 %) were seropositive for JEV. In 
addition, 35 out of 131 monkeys (26.7%) born in the facility were seropositive and the 
annual infection rate in the facility was estimated as 13%. Our results provide the 
evidence of frequent exposure of JEV to Japanese macaques, suggesting that there is a 
risk of JEV transmission to humans by mosquitoes.   
5.2. INTRODUCTION
Although only a few human JE cases have occurred in Japan, an annual 
serological survey of JEV in pigs showed that it was endemic especially in the western 
part of Japan (Arai et al., 2008). In addition, various wild and domestic mammals, 
including wild boars, raccoons, raccoon dogs and dogs were seropositive for JEV 
(Hamano et al., 2007; Nidaira et al., 2007; Ohno et al., 2009; Shimoda et al., 2010). 
Therefore, there is still a high risk of JEV infection in various mammals in Japan, 
especially in the western part.  
The seroprevalence of JEV among various species of monkeys has been 
examined previously. Cynomolgus monkeys (Macaca fascicularis), Japanese macaques 
(Macaca fuscata), green monkeys (Chlorocebus sabaeus) and pig-tailed macaques 
(Macaca nemestrina) were seropositive for JEV in several Asian countries (Inoue et al., 
2003; Nakgoi et al., 2013; Yamane 1974; Yuwono et al., 1984). In contrast, there was no 
evidence of JEV infection in toque macaques (Macaca sinica) in Sri Lanka where JEV is 
endemic (Peiris et al., 1993). Although there are reports of JEV infection in various 
monkey species in Asia, the recent prevalence in Japan remains unknown. Therefore, an 
assessment of the prevalence of JEV in monkeys in Japan will provide information about 
the potential risk of transmission of JEV infection to humans.  
In this chapter, I performed a serological survey of Japanese macaques using 
ELISA and assessed the current risk of JEV infection to monkeys in Japan.  
5.3. MATERIALS AND METHODS 
5.3.1. Cells
 African green monkey-originated Vero9013 cells (JCRB number; JCRB9013) 
and mosquito-originated C6/36 cells (JCRB number; IFO 50010) were used in this study. 
The condition of culture media are the same as described in CHAPTER 1. 
5.3.2. Virus 
 Swine-derived JEV/sw/Chiba/88/2002 (genotype I) were used in this study. The 
propagation of this virus was performed the same as described in CHAPTER 1. 
5.3.3. Monkey serum samples 
A total of 332 serum samples were collected from Japanese macaques (Macaca 
fuscata) housed at the Primate Research Institute (PRI), Kyoto University in Aichi 
Prefecture, Japan. Among them, 131 monkeys were born at PRI. All monkeys examined 
in this study were bled in the environment where they have chance to be bitten by 
mosquitoes frequently. These experiments were carried out according to rules of Kyoto 
University and guidelines for experimental animal welfare. Bleeding was performed 
under ketamine hydrochloride anesthesia. All sera used for ELISA were stored at -20°C 
until use.  
5.3.4. VN test 
The presence of VN antibody against JEV in sera was determined by 80% plaque 
reduction VN test described in CHAPTER 1.  
5.3.5. ELISA 
To determine the seroprevalence of JEV among monkeys, indirect ELISA using 
inactivated JEV, Beijing 01 strain, was carried out as described in CHAPTER 3. 
Peroxidase Conjugated Purified Recomb® Protein A/G (Thermo Fischer Scientific, 
Rockford, IL, U.S.A.) was used instead of a second antibody.  
5.3.6. Statistical analysis 
To analyze the results statistically, chi-square test was performed. p values of < 
0.05 were considered statistically significant. 
5.4. RESULTS 
5.4.1. Determination of cut-off value 
To determine the cut-off value, samples from 18 monkeys that were born after 
the last summer and had not experienced summer time yet and their mothers confirmed 
as JEV-negative by VN test, were examined by ELISA. The absorbance values obtained 
for these specimens ranged from 0.015 to 0.439, and the mean absorbance value was 
0.123 with a standard deviation (S.D.) of 0.107. The mean value plus 3 × S.D. (a value of 
0.444) was selected as the cut-off value between positive and negative results in this study.
Only one monkey whose mother was JEV-positive by VN test became JEV-positive in 
ELISA (Fig. 5-1) Since this baby monkey was three months old and had never spend the 
summer, the detected antibody must be originated from maternal antibody against JEV 
from its mother. 
5.4.2. Seroprevalence of JEV among monkeys in Japan 
 To survey JEV infection in monkeys in Japan, 332 serum samples were examined 
by ELISA. The results revealed that 146 out of 332 monkeys (44%) were seropositive for 
JEV. The seroprevalence among older monkeys (over 7 years old, 68%) was significantly 
higher than that among younger monkeys (0-3 years old, 12%) (p<0.05). There were no 
significant difference in seroprevalence between males (43%) and females (44%) (Table 
5-1).  
5.4.3. JEV infection to monkeys born and raised only in Aichi Prefecture, Japan 
 To determine the annual seroprevalence among monkeys in Japan, I focused on 
monkeys born and raised in the same facility in Aichi Prefecture. The results showed that 
35 out of 131 monkeys (27%) were seropositive for JEV (Table 5-2). The seroprevalence 
of JEV increased with age in these monkeys, which was consistent with results from other 
monkeys in Japan. The annual seroprevalence was calculated according to the assumption 
that JEV antibodies are maintained in Japanese macaques throughout their life. As a result, 
approximately 13% of monkeys were infected annually with JEV in Aichi Prefecture 
(Table 5-2). 
5.5. DISCUSSION 
The ELISA used in this study was established previously for surveillance of JEV 
among dogs in Thailand (CHAPTER 3; Shimoda et al., 2013). I adapted the method for 
surveillance of monkeys using protein A/G instead of a secondary antibody, and the 
results of ELISA were correlated with those of VN tests (data not shown). Therefore, this 
method can be used for surveillance in monkeys as well as dogs. Furthermore, protein 
A/G is reported to have a broad binding ability for various mammalian immunoglobulins 
including monkeys, deer, wild boar and raccoon dogs (Inoshima et al., 1999) which may 
mean it can be used for surveillance of JEV in many species of wild mammals.  
Serosurveys have indicated that the risk of JEV infection is higher in the western 
part of Japan than in eastern or northern parts (Arai et al., 2008; Shimoda et al., 2010). In 
this study, 27% of monkeys in Aichi Prefecture, which is located in the middle part of 
Japan, were seropositive for JEV. Therefore, there may be a higher risk of JEV infection 
in monkeys in western parts of Japan, such as Kyushu and Shikoku districts. One old 
serological study (before 1980s) on JEV prevalence in 34 Japanese macaques bred in 
Aichi Prefecture indicated that 29.7% of them were seropositive (Yuwono et al., 1984). 
In this study, 27% of Japanese macaques born in the same facility were seropositive for 
JEV. Therefore, the prevalence of JEV among monkeys appears to have been maintained 
since the 1980s. In addition, many macaques seropositive for JEV will be protected from 
the diseases by JEV, but not from JEV infection, because humans vaccinated with 
inactivated JEV vaccine developed NS1 antibody by natural infection of JEV without any 
severe symptoms (Konishi et al. 2002, Matsunaga et al. 2008).
To estimate the lowest annual seroprevalence of JEV, it was assumed that the 
antibody against JEV is maintained in Japanese macaques throughout their life. However, 
the duration of human antibody to JEV NS1 was estimated as 4.2 years (Konishi and Kitai, 
2009). Another study on JEV vaccination indicated that 18%, 47%, 82%, and 100% of 
human were estimated to become virus neutralization antibody negative at 5, 10, 15, and 
20 years after the second series of routine vaccination, respectively (Abe et al. 2007). In 
experimentally JEV-infected dogs, virus-neutralization titers kept increasing until 21-28 
days after infection, and slightly decreased at 70 days after infection (Shimoda et al. 2011). 
These reports indicated that JEV antibody are maintained for a long time, but not 
throughout their life. Therefore, the annual seroprevalence of JEV infection must be much 
higher, over 13%. 
In this study, the seroprevalence of JEV increased with the age of the monkeys. 
This result seems to be correlated with the period of exposure to JEV-infected mosquitoes. 
Although there is no available data about feeding pattern of Culex tritaeniorhynchus, 
main vector of JEV, against humans and non-human primates, some other mosquito 
species, such as Aedes and Haemagogus species, show a similar feeding pattern between 
humans and non-human primates (Marassa et al. 2009). Therefore, humans like Japanese 
macaques will be bitten by JEV-infected mosquitoes around this facility. However, since 
main amplifiers of JEV are pigs and birds, Japanese macaques must not be reservoir for 
transmission of JEV to human. 
In conclusion, since many Japanese macaques developed and maintained 
antibodies to JEV, there is a risk of JEV transmission to humans by JEV-carrying 
mosquitoes. In addition, since the prevalence of JEV among monkeys this facility has not 
changed over the last 30 years, continuous surveillance for JEV infection and vaccination 
of JEV in Japan is required. 
LEGEND FOR FIGURE 
Figure 5-1. ELISA values to JEV in infant Japanese macaques and their mother. The lanes 
-  in 
mother monkeys, respectively. Infant monkeys that were born after the last summer and 
their mothers were negative for JEV by VN test were assumed to be JEV negative for 
determination of the cut-off value. 
68 
69 
Table 5-1. Seroprevalence of JEV in Japanese macaques that were gathered from throughout Japan and raised in Aichi Prefecture, Japan. 
 Sex  Age 
Total 
 Male Female  0-3 4-7 8- 
No. of examined monkeys 111 221  105 73 154 332 
No. of positive monkeys 48 98  13 28 105 146 
% of positive monkeys 43 44  12 38 68 44 
70 
Table 5-2. Seroprevalence of JEV in Japanese macaques born and raised in the same facility in Aichi Prefecture, Japan. 
a: Annual positive rate was calculated according to assumption that the antibody against JEV is maintained in Japanese macaques throughout 
their life.  
 Sex  Age 
Total 
 Male Female  0-3 4-7 8- 
No. of examined monkeys 63 68  93 18 20 131 
No. of positive monkeys 17 18  13 8 14 35 
% of positive monkeys 27 26  1 44 70 27 
% of annual positive ratea 15 12  - - - 13 
6. CHAPTER 5 
Production and characterization of monoclonal antibodies  
to Japanese encephalitis virus 
6.1. ABSTRACT 
In this chapter, eighteen monoclonal antibodies (MAbs) to recent Japanese 
encephalitis virus (JEV) genotype I were produced and characterized by VN test, western 
blot analysis, indirect immunofluorescence assay and enzyme-linked immunosorbent 
assay. All MAbs recognized only envelope (E) protein or conformational epitope of E and 
precursor membrane (prM) proteins. Two MAbs (7E5 and 3-3H8) showed VN activity to 
JEV/sw/Chiba/88/2002 and JaOH0566, and the escape mutants were produced by 
addition of the MAbs to culture medium. All escape mutants possessed a change of 
glutamine to histidine at the position of 52 of E protein, suggesting that these neutralizing 
MAbs recognize the domain I-II hinge region of E protein. Five MAbs recognized all 
examined flaviviruses, two were specific to JEV and one was specific to JEV serocomplex. 
These MAbs may be useful for differentiation and diagnosis of flaviviruses. 
6.2. INTRODUCTION 
Many methods have been used for serological survey of JEV in various animals, 
such as VN test, hemagglutination inhibition (HI) assay and enzyme-linked 
the serological differentiation of flavivirus infections (Maeda et al., 2013). However, VN 
test requires a special facility, high level of technical skill, and a large volume of serum 
samples. In contrast, ELISA does not require the use of live virus and the procedure is 
simple and requires only a small amount of serum samples. I and other laboratories have 
reported the usability of indirect IgG ELISA for serological survey of JEV (Cui et al., 
2008; Hamano et al., 2007; Niwa et al., 1991; Shimoda et al., 2010; Xinglin et al., 2005; 
Yang et al., 2006). Although indirect ELISA allows us to examine a large number of 
samples at once, the cross-reactivity of the antibody with other flaviviruses obstructs us 
to perform the JEV-specific diagnosis. Dengue virus (DENV) and JEV have overlapped 
geographic distributions in several countries in Southeast Asia (Mackenzie et al., 2004), 
and also in Japan, both JEV and tick-borne encephalitis virus (TBEV) have spread. 
Therefore, diagnostic tools to differentiate JEV from other flaviviruses are required.  
In Asia including Japan, a main genotype of JEV has changed from genotype III 
et al., 2011; Ma et al., 2003; Nga et al., 2004; Pan et al., 2011). 
Although there is a report that antigenicity between genotypes I and III is different (Saito 
et al., 2007), the difference of antigenicity among JEV genotypes has been obscure.  
In this study, monoclonal antibodies to recent JEV genotype I were produced and 
the specificities were compared among various flaviviruses. 
6.3. MATERIALS AND METHODS 
6.3.1. Cells 
African green monkey-originated Vero cells (JCRB number; JCRB9013) and 
mosquito-originated C6/36 cells (JCRB number; IFO 50010) were used in this study. The 
condition of culture media are the same as described in CHAPTER 1. The P3U1 cells 
derived from mice myeloma cells were maintained in RPMI1640 (GIBCO) supplemented 
with 10% heat-inactivated FCS, 100 units/ml penicillin, 100 g/ml streptomycin and 55
M of 2-mercaptoethanol (GIBCO) at 37°C under 5% CO2. 
6.3.2. Viruses 
Human-derived JaOH0566 (genotype III) and swine-derived 
JEV/sw/Chiba/88/2002 (genotype I) were used in this study. The propagation of these 
viruses were performed the same as described in CHAPTER 1.  
6.3.3. Production of MAbs to JEV 
BALB/c mice (Five weeks old, male) were intraperitoneally immunized with 
JEV/sw/Chiba/88/2002 3 or 4 times at intervals of three weeks. The mice were euthanized 
3 to 7 days after the final immunization and the splenocytes were fused with P3U1 
myeloma cells by using 50% polyethylene glycol solution (Hybri-MaxTM; Sigma-Aldrich, 
St. Louis, Mo, U.S.A.). The hybridoma cells were diluted in selection media, GIT media 
(Wako, Osaka, Japan) containing 2% hypoxanthine-aminopterin-thymidine (HAT) 
supplement (GIBCO), 10% BM-Condimed H1 Hybridoma Cloning Supplement (Roche 
Diagnostics, Mannheim, Germany) and 10% FCS, and incubated for 7 to 10 days at 37°C 
and 5% CO2. The screening of hybridomas was performed by either VN test or indirect 
immunofluorescence assay (IFA) using JEV/sw/Chiba/88/2002 as described below. 
Hybridomas producing MAbs specific for JEV were selected and subsequently cloned by 
the limiting dilution method. The cloned hybridomas were intraperitoneally injected into 
pristane-treated BALB/c mice (Five weeks old, male) to produce ascites. The 
immunoglobulin subclass of MAbs was determined using an IsoStrip Mouse Monoclonal 
Antibody Isotyping Kit (Roche Applied Science) according to the 
instructions.  
6.3.4. VN test 
To determine the VN activity of MAbs, VN test was carried out as described in 
CHAPTER 1.  
6.3.5. ELISA 
ELISA was carried out using inactivated JEV, Beijing 01 strain, as described in 
CHAPTER 3. Peroxidase-conjugated goat anti-mouse IgG+A+M (Cappel Laboratories, 
Cochranville, PA, U.S.A.) was used as a second antibody.  
6.3.6. Western blot analysis 
Vero cells were infected with JEV/sw/Chiba/88/2002, and then incubated at 
37°C and 5% CO2 until cytopathic effect (CPE) was observed. The cells were removed 
from dishes with 0.02% EDTA in PBS. After centrifugation at 200  g for 5 min at 4°C, 
the supernatant was removed and the cells were suspended in PBS. Then, suspended cells 
were mixed with equal volume of 2  concentrated sample buffer (6.25 mM Tris-HCl 
(pH 6.8), 2% sodium dodecyl sulfate (SDS), 20% glycerol, 0.001% bromophenol blue). 
These samples were boiled for 3 min, placed on ice for 3 min and centrifuged at 13,000 
g for 3 min at room temperature. Then, the cell lysates were electrophoresed on 10% 
SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon-
P; Millipore, Billerica, MA, U.S.A.). After blocking with Tris-buffered saline (TBS) 
containing 3% gelatin (EIA Grade Reagent Gelatin; Bio-Rad) for 45 min at 37°C, the 
membrane was washed three times with TBS containing 0.05% Tween 20 (T-TBS). After 
incubation with diluted MAbs for 45 min at 37°C, the membrane was washed three times 
with T-TBS. Then, the membrane was reacted with peroxidase-conjugated goat anti-
mouse IgG+A+M (Cappel Laboratories) for 45 min at 37°C. After washing the membrane 
with T- -
diaminobenzidine tetrahydrochloride (DAB; Wako) 
6.3.7. Construction of plasmids and transfection to cells 
Viral RNA was extracted from virus-infected Vero cells using QIAGEN RNeasy 
Mini Kit (QIAGEN, Germantown, MD, U.S.A.
instructions. First strand cDNA was transcribed by RNA LA PCRTM Kit (AMV) Ver.1.1 
(TAKARA, Shiga, Japan) using random 9 mer at 30°C for 10 min, 42°C for 30 min, 70°C 
for 15 min and 4°C for 5 min. The cDNA was amplified using primer pairs, EcoprMF (5'-
ACA GAA TTC ACC ATG GGA GGA AAT GAA AGC TCG-3') and BglMR (5'-ACA 
AGA TCT TCA ACT GTA AGC CGG AGC GAC C-3') for prM, EcoprMF and BglER 
(5'-ACA AGA TCT TCA GGC ATG CAC ATT GGT CGC-3') for prME, and EcoEF (5'-
ACA GAA TTC ACC ATG CAA CGT GTG GTG TTT ACT ATT C-3') and BglER for E. 
Amplified cDNAs were treated with restriction enzymes EcoRI and BglII, and then 
cloned in the EcoRI-BglII site of pCAGGS plasmid (Niwa et al., 1991). The resultants 
were named as pCAG-prM, pCAG-E and pCAG-prME, respectively. Then, 293T cells 
were transfected with expression plasmids using LipofectamineTM LTX and PlusTM
Regent (Invitrogen, Carlsbad, CA, U.S.A.) and analyzed by IFA. 
6.3.8. IFA 
Subconfluent monolayers of Vero cells were infected with viruses, including JEV 
genotype I (JEV/sw/Chiba/88/2002, JEV/eq/Tottori/2003, Jakagawa2000), JEV genotype 
III (JaOH0566, JaGAr-01), JEV genotype V (Muar), Murray Valley encephalitis virus 
(MVEV), WNV (NY99), DENV serotype 1 (Hawaii), serotype 2 (NC), serotype 3 (H87), 
serotype 4 (H241), yellow fever virus (YFV) (17D), and TBEV (Sofin). After incubation 
at 37°C and 5% CO2 until CPE was observed, infected cells were removed from dishes 
with 0.02% EDTA in PBS. After centrifugation at 200 g for 5 min at 4°C, the 
supernatant was removed and the cells were suspended in PBS. The cells were placed on 
micro slide glass (Matsunami, Osaka, Japan), air-dried, and fixed with cold acetone for 
10 min at -20°C. 293T cells transfected with expression plasmids were also treated the 
same as described above. Then, the cells were incubated with MAbs at 37°C for 30 min. 
After washing the cells three times with PBS, fluorescein-conjugated goat anti-mouse 
IgM+IgG+IgA (Southern Biotech, Birmingham, AL, U.S.A.) was added and the cells 
were incubated for 30 min. The cells were washed three times with PBS and preserved 
with mounting fluid, 90% glycerol in 0.05M sodium carbonate and 0.05M sodium 
hydrogen carbonate. Cells were examined using a Nikon Optiphot-2 EFD-3 Fluorescence 
phase contrast Microscope (Nikon Corporation, Tokyo, Japan).   
6.3.9. Selection of neutralization-resistant escape mutant 
Neutralization-resistant escape mutants were selected by harvesting JEV in Vero 
cells in the presence of neutralizing MAbs (7E5, 3-3H8). Briefly, Vero cells were infected 
with JEV/sw/Chiba/88/2002 or JaOH0566 at a multiplicity of infection of 0.01. After 
incubation at 37 °C for 90 min, cells were washed twice and EMEM containing 2% FCS 
and 1 % ascites of MAbs was added. The supernatant was collected when CPE was 
observed. After repeating these steps three times, the supernatant was cloned by plaque 
cloning and the obtained mutants were confirmed by IFA. The escape mutants were 
named as 7E5 mar Chiba, 7E5 mar JaOH0566 and 3-3H8 mar Chiba.  
6.3.10. Sequence analysis 
Viral RNA was extracted from virus-infected Vero cells using QIAGEN RNeasy 
Mini Kit (QIAGEN) 
transcribed by RNA LA PCRTM Kit (AMV) Ver.1.1 (TAKARA) using random 9 mer at 
30°C for 10 min, 42°C for 30 min, 70°C for 15 min and 4°C for 5 min. To analyze the 
nucleotide sequences of JEV structural proteins (C, prM, E), cDNA was amplified by 
PCR using a primer pair J8 (nt 1-18) and J6 (nt 2845-3865) (Yun et al., 2003) at 94°C for 
2 min, followed by 30 cycle of denaturation at 94°C for 30 sec, annealing at 65°C 30 sec, 
and extension at 72°C for 4 min. PCR products were electrophoresed on 0.8% agarose 
gel and an approximately 4 kbp fragment was purified with the QIAGEX-  Gel 
Extraction Kit (QIAGEN) and analyzed by direct sequencing with the BigDye Terminator 
Cycle Sequencing Kit ver3.1 (Applied Biosystems, Austin, TX, U.S.A.) according to the 
6.4. RESULTS 
6.4.1. Production and characterization of MAbs against JEV 
Total of 18 hybridomas were finally isolated and cloned. The heavy chain 
subclasses of MAbs were determined as described in Table 6-1, and their light chains 
were all kappa isotype. 
To determine the protein recognized by MAbs, expression plasmids, pCAG-prM, 
pCAG-E, pCAG-prME and a mixture of pCAG-prM and pCAG-E were transfected to 
293T cells and IFA was carried out. All MAbs recognized prME protein and co-expressed 
prM and E. Among them, seven recognized E protein alone and none recognized prM 
protein alone (Table 6-1). Three MAbs (3-1A5, 3-2D6, 3-3B10) recognized a molecular 
mass of 50 kDa by western blot analysis under non-reducing condition (Table 6-1).  
To determine the binding ability to purified vaccine antigen, Beijing 01 
(genotype III), ELISA was performed. Six MAbs (3-1A1, 3-1A5, 3-2A1, 3-2D6, 3-4B3 
and 3-3B10) showed high reactivity with purified JEV antigen (Absorbance > 3.5), while 
three MAbs (1-1A7, 3-1C2, 4-3E8) showed no or less reactivity (Absorbance < 1.0) 
(Table 6-1). 
6.4.2. Cross-reactivity of MAbs to various flaviviruses 
To determine the cross-reactivity of the MAbs with various flaviviruses 
including genotypes I, III and V of JEV, MVEV, WNV, serotypes 1, 2, 3 and 4 of DENV, 
YFV, and TBEV, each MAb was examined by IFA using Vero cells infected with these 
viruses. As the result, five MAbs (3-1A1, 3-1A5, 3-2A1, 3-2D6, 3-4B3) cross-reacted 
with all flaviviruses examined in this study and two MAbs (3-1A2, 4-4A8) specifically 
recognized all genotypes of JEV (Table 6-2). One MAb (3-1D7) recognized JEV, MVEV, 
and WNV, suggesting that 3-1D7 is specific for JEV serocomplex (Table 6-2). 
6.4.3. Analysis of escape mutants 
To identify the epitope recognized by MAbs with VN activity, these escape 
mutants, 7E5 mar Chiba, 3-3H8 mar Chiba and 7E5 mar JaOH0566, were selected by 
harvesting JEV in the presence of MAb 7E5 or 3-3H8. Viral genome encoding C, prM 
and E was compared between parent strains and escape mutants. As the result, only one 
amino acid change was identified in the E proteins of 7E5 mar Chiba and 3-3H8 mar 
6-3). Based on these 
sequence analysis of escape mutants, MAbs 7E5 and 3-3H8 recognized the domain I-II 
hinge region of E protein, which has been previously described as an important 
neutralizing epitope for JEV (Hasegawa et al., 1992; Kobayashi et al., 1985; Luca et al., 
2012; Morita et al., 2001). 
6.5. DISCUSSION 
In this study, 18 MAbs to a recent field isolate belonging to genotype I were 
produced and characterized. Among them, two MAbs (3-1A2, 4-4A8) were specific to 
JEV, and one MAb (3-1D7) was to JEV serocomplex. In contrast, five MAbs (3-1A1, 3-
1A5, 3-2A1, 3-2D6, 3-4B3) were cross-reactive among all flaviviruses, including MVEV, 
WNV, DENV, YFV and TBEV. These JEV- or JEV serocomplex-specific MAbs and 
cross-reactive MAbs may be useful for the detection of flaviviruses and may be applicable 
for the differentiation of JEV infection from other flavivirus infection by 
immunohistochemistry and competitive ELISA using these MAbs.  
I showed that MAbs 7E5 and 3-3H8 recognized the same epitope located on the 
domain I-II hinge region of E protein. Specifically, sequence analysis of 7E5 and 3-3H8 
has been previously described as an important epitope recognized by MAbs against JEV 
with strong neutralizing activity (Hasegawa et al., 1992; Kobayashi et al., 1985; Luca et 
al., 2012; Morita et al., 2001), confirming that the domain I-II hinge region of E protein 
is a major target of VN antibody.  
All MAbs in this study recognized prME protein, and among them seven MAbs 
recognized E protein alone and none did prM protein alone. The previous study indicates 
that the prM protein assists in the proper folding of E protein (Konishi et al., 1993). 
Therefore, the other eleven MAbs may recognize the conformational epitope in the 
presence of prM protein.  
In conclusion, eighteen MAbs to JEV possessed different reactivity with 
flaviviruses. As several flaviviruses have been endemic in some regions, these MAbs 
should be the useful tools to detect flavivirus infection and to differentiate JEV infection 
from the other flavivirus infections. 
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 Table 6-1. Characterization of MAbs 
a 100-fold diluted mouse ascites was used for IFA, ELISA and western blot analysis. 
b NT: Not tested 
MAbs Isotype IFA
a
ELISAa (G III) Western blot
a
(G I) 
 VN test 
prM E prME prM+E    Chiba (G I) JaOH0566 (G III) 
3-1A1 IgG2a - + + +  >3.50  -  <1:100 NTb
3-1A5 IgG2a - + + +  >3.50  +  <1:100 NT
3-2A1 IgG2a - + + +  >3.50  -  <1:100 NT
3-2D6 IgG2a - + + +  >3.50  +  <1:100 NT
3-4B3 IgG2a - + + +  >3.50  -  <1:100 NT
3-3B10 IgG2b - + + +  >3.50  +  <1:100 NT
1-1A7 IgM - - + +  0.05  -  <1:100 NT
3-1D7 IgG3 - - + +  2.40  -  <1:100 NT
3-3D1 IgM - - + +  2.05  -  <1:100 NT
4-4E9 IgG2a - - + +  1.82  -  <1:100 NT
3-2D1 IgM - - + +  2.35  -  <1:100 NT
3-1A2 IgG2a - - + +  2.38  -  <1:100 NT
4-4A8 IgM - - + +  3.30  -  <1:100 NT
3-1C2 IgG2a - - + +  0.09  -  <1:100 NT
3-1B5 IgG2a - - + +  2.53  -  <1:100 NT
7E5 IgM - - + +  1.53  -  1:102400 1:102400 
3-3H8 IgM - - + +  1.65  -  1:102400 1:204800 
4-3E8 IgG2a - + + +  0.28  -  <1:100 NT
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Table 2. Cross-reactivity of mAbs against various flaviviruses 
MAbs 
JEV GI JEV GIII JEV 
GV MVEV WNV 
DENV 
YFV TBEV 
Chiba Tottori Kagawa JaOH JaGAr 1 2 3 4 
3-1A1 + + + + + + + + + + + + + + 
3-1A5 + + + + + + + + + + + + + + 
3-2A1 + + + + + + + + + + + + + + 
3-2D6 + + + + + + + + + + + + + + 
3-4B3 + + + + + + + + + + + + + + 
3-3B10 + + + + + + + + + + + + + - 
1-1A7 + + + + + + - + + + + + - - 
3-1D7 + + + + + + + + - - - - - - 
3-3D1 + + + + + + - + - - - - - - 
4-4E9 + + + + + - + + - - - - - - 
3-2D1 + + + + + + + - - - - - - - 
3-1A2 + + + + + + - - - - - - - - 
4-4A8 + + + + + + - - - - - - - - 
3-1C2 + + + - + + - - - - - - - - 
3-1B5 + + + + + - - - - - - - - - 
7E5 + + - + - - - - - - - - - - 
3-3H8 + + - + - - - - - - - - - - 
4-3E8 + + - + - - - - - - - - - - 
a: IFA was performed using 100-fold diluted mouse ascites.
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 Table 3. Amino acid changes in neutralization-resistant escape mutants   
Viruses 
E52 E276 
(Domain II) (Domain II) 
Parents  
Chiba Q S 
JaOH0566 Q S 
Escape mutants  
7E5 mar Chiba H S 
3-3H8 mar Chiba H S 
7E5 mar JaOH0566 H R 
7. GENERAL CONCLUSION 
In this dissertation, to understand the present situation of JEV, author examined 
the seroprevalence of JEV among dogs, cats and monkeys in Japan and dogs in Thailand 
using classical and our established novel method for detecting antibodies against JEV. 
Also, for further development of novel, simple, and specific method to detect both 
antibody and antigen of JEV, MAbs were produced.  
The ideal sentinels for serological survey would be susceptible to infection, 
survive from the infection, develop detectable antibodies, pose no risk of infection to 
handlers, and never develop a high level of viremia enough to infect vector mosquitoes 
(Resnick et al., 2008). The study in CHAPTER 1 found the risk of JEV infection remains 
high, even in urban/residential areas, by using dogs as sentinels, and in CHAPTER 2, it 
was confirmed that dogs fulfil the requirements as a good sentinel for serosurvey of JEV 
infection. Therefore, it is recommended that annual JEV surveillance should be carried 
out in pigs in Japan and that dogs should be surveyed every several years to assess the 
risk of JEV infection in humans in urban/residential areas. 
In CHAPTER 3, a novel method for serosurvey of JEV was developed. An 
indirect ELISA using JEV antigen was established and applied for the detection of JEV 
antibodies in dogs; this assay allowed us to examine a large number of samples at once 
and to assess the levels of anti-JEV immunoglobulins in canine specimens quantitatively. 
This simple method is expected to facilitate the assessment of the human risk of JEV 
infection. 
In CHAPTER 4, seroprevalence among non-human primates in Japan was 
described, and revealed that many Japanese macaques possessed antibody against JEV. 
Therefore, there may be a risk of JEV transmission to humans by JEV-carrying 
mosquitoes. In addition, since the prevalence of JEV among monkeys in Japan had not 
changed over 30 years, we have to keep giving an attention to JEV infection in Japan. 
In CHAPTER 5, eighteen MAbs to JEV were produced and each possessed 
different reactivity with flaviviruses. As several flaviviruses have been endemic in some 
regions, these MAbs must be the useful tools to detect flavivirus infection and to 
differentiate JEV infection from the other flavivirus infection.
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